abrdn plc Decreases Position in Guardant Health, Inc. (NASDAQ:GH)

abrdn plc lowered its stake in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 19.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 442,951 shares of the company's stock after selling 109,522 shares during the period. abrdn plc owned approximately 0.36% of Guardant Health worth $13,532,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in GH. JNBA Financial Advisors bought a new stake in Guardant Health in the 3rd quarter worth about $26,000. R Squared Ltd purchased a new position in shares of Guardant Health in the 4th quarter worth approximately $26,000. Ashton Thomas Securities LLC bought a new position in shares of Guardant Health in the third quarter valued at approximately $34,000. Nisa Investment Advisors LLC grew its position in Guardant Health by 168.1% during the third quarter. Nisa Investment Advisors LLC now owns 3,434 shares of the company's stock valued at $79,000 after buying an additional 2,153 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Guardant Health by 21.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company's stock worth $102,000 after acquiring an additional 796 shares during the period. Institutional investors own 92.60% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Guardant Health from $48.00 to $50.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. Leerink Partners cut their target price on Guardant Health from $60.00 to $50.00 and set an "outperform" rating for the company in a research note on Thursday, October 17th. The Goldman Sachs Group lifted their target price on Guardant Health from $36.00 to $49.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. Guggenheim restated a "buy" rating on shares of Guardant Health in a research report on Wednesday, January 22nd. Finally, Sanford C. Bernstein decreased their target price on shares of Guardant Health from $40.00 to $35.00 and set an "outperform" rating on the stock in a report on Wednesday, October 30th. Sixteen research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $42.63.

Guardant Health Stock Down 1.8 %

Guardant Health stock traded down $0.80 during trading hours on Tuesday, hitting $43.60. The stock had a trading volume of 1,545,680 shares, compared to its average volume of 2,514,484. The stock has a market capitalization of $5.39 billion, a P/E ratio of -10.28 and a beta of 1.32. Guardant Health, Inc. has a 12-month low of $15.81 and a 12-month high of $50.89. The stock's 50-day moving average price is $38.45 and its 200-day moving average price is $30.81.

Insider Buying and Selling

In other Guardant Health news, Director Musa Tariq sold 2,320 shares of the business's stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $35.00, for a total transaction of $81,200.00. Following the completion of the sale, the director now owns 2,676 shares of the company's stock, valued at approximately $93,660. The trade was a 46.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Meghan V. Joyce sold 2,896 shares of the business's stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total value of $86,590.40. Following the transaction, the director now owns 7,648 shares of the company's stock, valued at approximately $228,675.20. This trade represents a 27.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,548 shares of company stock valued at $179,782 over the last 90 days. Company insiders own 5.50% of the company's stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.